Neupath Health Inc. ( (TSE:NPTH) ) just unveiled an update.
NeuPath Health Inc. reported a 12% year-over-year increase in fourth-quarter revenue, reaching $18.9 million, and a 19% rise in full-year adjusted EBITDA. The company achieved significant milestones, including the first North American injection of Arthrosamid at its Mississauga clinic and securing a $13.5 million credit facility with National Bank to support growth initiatives. These developments underscore NeuPath’s commitment to expanding its services and improving patient care, positioning it for continued growth in the chronic pain treatment sector.
More about Neupath Health Inc.
NeuPath Health Inc. operates a network of clinics specializing in chronic pain treatment. The company focuses on delivering category-leading services in this niche, aiming to expand its reach and enhance patient care through innovative procedures and strategic financial partnerships.
YTD Price Performance: -6.82%
Average Trading Volume: 113,115
Technical Sentiment Signal: Sell
Current Market Cap: C$11.12M
For detailed information about NPTH stock, go to TipRanks’ Stock Analysis page.